tetano
Editor, Senior Moderator
Front Microbiol
. 2023 Nov 27:14:1292735.
doi: 10.3389/fmicb.2023.1292735. eCollection 2023. Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China
Guichan Liao[SUP] #[/SUP][SUP] 1 [/SUP], Muye Xia[SUP] #[/SUP][SUP] 1 [/SUP], Yuanhui Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Hongjie Chen[SUP] 1 [/SUP], Wei Liao[SUP] 2 [/SUP], Jie Peng[SUP] 1 [/SUP], Shaohang Cai[SUP] 1 [/SUP]
Affiliations
Introduction: There are limited data on the efficacy of baloxavir marboxil (baloxavir) versus oseltamivir in Chinese patients with influenza A.
Methods: This study is an observational real-world investigation encompassing 246 patients (baloxavir, n = 147; oseltamivir, n = 99) confirmed positive for influenza A. The choice between baloxavir and oseltamivir antiviral treatments was determined collaboratively by the clinician and the patient. A thorough comparative analysis was undertaken between the two groups, examining parameters such as the duration of fever and symptoms, viral load dynamics, lymphocyte changes, and enhancements in health-related quality of life (QoL).
Results: No significant differences were observed in demographic data between the two groups. The duration of fever was significantly shorter in the baloxavir group (P < 0.001). However, the duration of symptoms was not significant different (P = 0.167). Multivariable Cox analysis showed the independent factors affecting duration of fever were baloxavir treatment (HR = 2.033, P < 0.001), fever on day 1 (HR = 0.741, P = 0.010) and CRP level (HR = 1.009, P = 0.039). Moreover, sex (HR= 0.660, P = 0.019) and monocyte count (HR = 1.355, P = 0.018) were independent factors affecting the duration of symptoms. No significant difference in change of health-related quality of life (P > 0.05), positive rate of viral antigen on day 3 (P = 0.477) between the two groups. Remarkably, a mutation was observed in one case on the third-day after baloxavir treatment compared with first-day, from cysteine to serine at position 384 of the PA subunit.
Conclusion: In the clinical setting, baloxavir demonstrated comparable clinical benefits to oseltamivir, establishing its efficacy as an effective antiviral therapy for Chinese patients with influenza.
Keywords: baloxavir; duration of fever; influenza; oseltamivir; quality of life.
. 2023 Nov 27:14:1292735.
doi: 10.3389/fmicb.2023.1292735. eCollection 2023. Prospective observational study of baloxavir marboxil in adults and adolescents with uncomplicated influenza from China
Guichan Liao[SUP] #[/SUP][SUP] 1 [/SUP], Muye Xia[SUP] #[/SUP][SUP] 1 [/SUP], Yuanhui Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Hongjie Chen[SUP] 1 [/SUP], Wei Liao[SUP] 2 [/SUP], Jie Peng[SUP] 1 [/SUP], Shaohang Cai[SUP] 1 [/SUP]
Affiliations
- PMID: 38088961
- PMCID: PMC10711061
- DOI: 10.3389/fmicb.2023.1292735
Introduction: There are limited data on the efficacy of baloxavir marboxil (baloxavir) versus oseltamivir in Chinese patients with influenza A.
Methods: This study is an observational real-world investigation encompassing 246 patients (baloxavir, n = 147; oseltamivir, n = 99) confirmed positive for influenza A. The choice between baloxavir and oseltamivir antiviral treatments was determined collaboratively by the clinician and the patient. A thorough comparative analysis was undertaken between the two groups, examining parameters such as the duration of fever and symptoms, viral load dynamics, lymphocyte changes, and enhancements in health-related quality of life (QoL).
Results: No significant differences were observed in demographic data between the two groups. The duration of fever was significantly shorter in the baloxavir group (P < 0.001). However, the duration of symptoms was not significant different (P = 0.167). Multivariable Cox analysis showed the independent factors affecting duration of fever were baloxavir treatment (HR = 2.033, P < 0.001), fever on day 1 (HR = 0.741, P = 0.010) and CRP level (HR = 1.009, P = 0.039). Moreover, sex (HR= 0.660, P = 0.019) and monocyte count (HR = 1.355, P = 0.018) were independent factors affecting the duration of symptoms. No significant difference in change of health-related quality of life (P > 0.05), positive rate of viral antigen on day 3 (P = 0.477) between the two groups. Remarkably, a mutation was observed in one case on the third-day after baloxavir treatment compared with first-day, from cysteine to serine at position 384 of the PA subunit.
Conclusion: In the clinical setting, baloxavir demonstrated comparable clinical benefits to oseltamivir, establishing its efficacy as an effective antiviral therapy for Chinese patients with influenza.
Keywords: baloxavir; duration of fever; influenza; oseltamivir; quality of life.